Addex Therapeutics Ltd
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Addex Therapeutics Ltd is a clinical-stage pharmaceutical company that focuses on the development and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of drugs known as allosteric modulators, which are designed to treat neurological disorders. Leveraging its proprietary drug discovery platform, Addex develops a portfolio of innovative therapies aimed at modulating receptors and other proteins that are considered attractive targets for treating various central nervous system conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-30 02:00 |
Earnings Release
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results …
|
English | 16.7 KB | ||
| 2025-09-26 02:00 |
Report Publication Announcement
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Result…
|
English | 5.8 KB | ||
| 2025-09-23 02:00 |
Regulatory News Service
Addex Appoints Bank of New York Mellon as Depositary Bank
|
English | 4.7 KB | ||
| 2025-06-30 02:00 |
Related Party Transaction
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine …
|
English | 7.3 KB | ||
| 2025-06-25 02:00 |
Post-Annual General Meeting Information
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
English | 5.6 KB | ||
| 2025-06-19 02:00 |
Earnings Release
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Upd…
|
English | 13.7 KB | ||
| 2025-06-18 02:00 |
Report Publication Announcement
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Cal…
|
English | 5.9 KB | ||
| 2025-06-06 02:00 |
Regulatory News Service
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple…
|
English | 7.4 KB | ||
| 2025-06-05 02:00 |
Regulatory News Service
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cou…
|
English | 6.4 KB | ||
| 2025-06-03 02:00 |
Pre-Annual General Meeting Information
Addex Convenes Annual General Meeting 2025
|
English | 6.8 KB | ||
| 2025-05-12 02:00 |
Regulatory News Service
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Suc…
|
English | 6.6 KB | ||
| 2025-01-08 01:00 |
Regulatory News Service
Addex to Present at the 2025 Swiss Equities Baader Conference
|
English | 5.2 KB | ||
| 2024-11-22 01:00 |
Earnings Release
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
English | 17.7 KB | ||
| 2024-11-11 01:00 |
Report Publication Announcement
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…
|
English | 7.1 KB | ||
| 2024-09-30 02:00 |
Earnings Release
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results …
|
English | 17.2 KB |
Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Addex Therapeutics Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
